Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10335750 | 0.88 | P2RX7 (0.37) | P2RX7HPGDHTTPDE10AGABRA1 | |
| SCHEMBL19196278 | 0.87 | GABRA1 (0.39) | P2RX7GABRA1GABRB2RIPK1CTRC | |
| SCHEMBL19887751 | 0.82 | P2RX7 (0.40) | P2RX7HPGDHTTKDM5AKDM5B | |
| SCHEMBL19887771 | 0.82 | P2RX7 (0.40) | P2RX7HPGDHTTKDM5AKDM5B | |
| SCHEMBL27073675 | 0.82 | P2RX7 (0.36) | P2RX7HPGDHTTKDM5AKDM5B | |
| SCHEMBL10301629 | 0.82 | NOTUM (0.35) | P2RX7HPGD | |
| SCHEMBL15133727 | 0.81 | P2RX7 (0.34) | P2RX7HPGDHTTHDAC3HDAC4 | |
| SCHEMBL12844610 | 0.81 | CTSL (0.40) | P2RX7HPGDHTTPDE10AFEN1 | |
| SCHEMBL24132225 | 0.81 | FEN1 (0.36) | FEN1 | |
| SCHEMBL489837 | 0.80 | P2RX7 (0.36) | P2RX7HPGDHTTKDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873438-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20230287272-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DEVICE | DIC CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | DIC CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3416962-B1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI SA (FR) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020023560-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG | 2020-01-30 | — | — | WO | disclosed |
| EP-2982730-B1 | LIQUID-CRYSTALLINE MEDIUM AND HIGH-FREQUENCY COMPONENTS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2019-10-16 | — | — | EP | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180208846-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | DIC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | SANOFI (FR) | 2012-12-13 | — | — | US | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008077555-A2 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | P2RX7 225/4885HPGD 1808/4885HTT 945/4885 |
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | P2RX7 3755/4885HPGD 4638/4885HTT 4816/4885 |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | SFXN1, SFXN3, SIK3 | P2RX7 4614/4885HPGD 3932/4885HTT 4747/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | P2RX7 4424/4885HPGD 461/4885HTT 3870/4885 |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | MYLK2, RHOT2, MYLK | P2RX7 4445/4885HPGD 1122/4885HTT 1744/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | P2RX7 741/4885HPGD 2270/4885HTT 3359/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | P2RX7 790/4885HPGD 2313/4885HTT 3337/4885 |
| US-11639327-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display device using the same | SKP1, PKN1, KTN1 | P2RX7 2580/4885HPGD 3702/4885HTT 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.